Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine KinasesHideko Isozaki, Katsuyuki Kiura|Cancer Research|2016Cited by 128
Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer CellsKammei Rai, Katsuyuki Kiura|Molecular Cancer Therapeutics|2011Cited by 126
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancersHiromi Watanabe, Katsuyuki Kiura|Cancer Science|2021Cited by 54
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibKiichiro Ninomiya, Katsuyuki Kiura|Scientific Reports|2018Cited by 47
<scp>JAK</scp>2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutationDaijiro Harada, Katsuyuki Kiura|Cancer Science|2012Cited by 45